clinical trial · NCT06468826
A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)
Amgen·phase1·completed·n = 13
End-Stage Renal Disease (ESRD)Avacopan
brief summary
The primary objective of the study is to evaluate the pharmacokinetics (PK) of avacopan and metabolite (M1) after a single dose of avacopan in participants with normal renal function and participants with ESRD requiring hemodialysis (HD).
started
Jun 18, 2024
primary completion
Oct 5, 2024
completion
Oct 5, 2024
last updated
Mar 25, 2026
official title
A Phase 1, Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Avacopan in Subjects With Normal Renal Function and Subjects With End-Stage Renal Disease (ESRD) Requiring Hemodialysis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol